Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Acquisitions & Divestments (2023 - 2025)

InMed Pharmaceuticals (INM) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $4199.0 in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 56.8% year-over-year to $4199.0; the TTM value through Dec 2025 reached $43424.0, down 3.0%, while the annual FY2025 figure was $42270.0, 0.45% changed from the prior year.
  • Change in Acquisitions & Divestments reached $4199.0 in Q4 2025 per INM's latest filing, down from $20957.0 in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $21324.0 in Q3 2024 and bottomed at -$431.0 in Q2 2024.
  • Average Change in Acquisitions & Divestments over 3 years is $12167.6, with a median of $16037.0 recorded in 2025.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 617.63% in 2025, down 24.34% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $21317.0 in 2023, then plummeted by 87.44% to $2678.0 in 2024, then skyrocketed by 56.8% to $4199.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $4199.0 in Q4 2025, $20957.0 in Q3 2025, and $2231.0 in Q2 2025.